Moberg Pharma AB Overview
Company Headquarters: Bromma, Sweden
Founded: 2006
Company Working:
Moberg Pharma AB develops patented topical pharmaceuticals for the treatment of common disorders through the use of innovative drug delivery. The company comprises only one area of operation, which is the development and commercialization of medical products. MOB-015 is the next generation of nail fungus treatment and BUPI is a new pain treatment for mouth and throat for cancer patients with oral mucositis. MOB-015 is currently undergoing two parallel phase 3 studies with expected topline results towards the end of 2019 and the second quarter of 2020, respectively. It has also signed two license agreements with leading players in Europe and Canada. It markets its products directly in the US, as well as through a network of distributors in approximately 40 countries.
Strategy
Moberg Pharma AB thrives to offer high-quality products that meet customer needs and regulatory requirements. Innovation and quality assessment have always been a key criterion to manufacture its products. Moreover, it aims to get actively involved in mergers and acquisitions to increase market penetration.
